Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 1
1981 1
1982 1
1986 1
1989 1
1992 1
1994 1
1995 1
2002 1
2004 1
2005 2
2007 2
2008 1
2009 1
2010 5
2011 2
2012 2
2014 1
2016 2
2017 3
2018 4
2020 2
2021 5
2022 4
2023 4
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S. Fleischhacker WW, et al. Among authors: desch m. Lancet Psychiatry. 2021 Mar;8(3):191-201. doi: 10.1016/S2215-0366(20)30513-7. Lancet Psychiatry. 2021. PMID: 33610228 Clinical Trial.
cGK substrates.
Schlossmann J, Desch M. Schlossmann J, et al. Among authors: desch m. Handb Exp Pharmacol. 2009;(191):163-93. doi: 10.1007/978-3-540-68964-5_9. Handb Exp Pharmacol. 2009. PMID: 19089330 Review.
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Schölch C, Desch M, Hennige AM. Jungnik A, et al. Among authors: desch m. Diabetes Obes Metab. 2023 Apr;25(4):1011-1023. doi: 10.1111/dom.14948. Epub 2023 Jan 30. Diabetes Obes Metab. 2023. PMID: 36527386 Clinical Trial.
NOACs for treatment of venous thromboembolism in clinical practice.
Schulman S, Singer D, Ageno W, Casella IB, Desch M, Goldhaber SZ. Schulman S, et al. Among authors: desch m. Thromb Haemost. 2017 Jun 28;117(7):1317-1325. doi: 10.1160/TH17-01-0065. Epub 2017 Apr 20. Thromb Haemost. 2017. PMID: 28424821 Review.
IRAG and novel PKG targeting in the cardiovascular system.
Schlossmann J, Desch M. Schlossmann J, et al. Among authors: desch m. Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H672-82. doi: 10.1152/ajpheart.00198.2011. Epub 2011 Jun 10. Am J Physiol Heart Circ Physiol. 2011. PMID: 21666108 Free article. Review.
Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
Desch M, Schlecker C, Hohl K, Liesenfeld KH, Chan T, Müller F, Wunderlich G, Keller S, Ishiguro N, Wind S. Desch M, et al. J Clin Psychopharmacol. 2023 Mar-Apr 01;43(2):113-121. doi: 10.1097/JCP.0000000000001656. Epub 2023 Jan 26. J Clin Psychopharmacol. 2023. PMID: 36700734 Free PMC article. Clinical Trial.
49 results